Wedekind MF - Search Results

1

Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma.

Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP. Wedekind MF, et al. iScience. 2021 Jun 19;24(7):102759. doi: 10.1016/j.isci.2021.102759. eCollection 2021 Jul 23. iScience. 2021. PMID: 34278266 Free PMC article.

2

Immunotherapy for osteosarcoma: Where do we go from here?

Wedekind MF, Wagner LM, Cripe TP. Wedekind MF, et al. Pediatr Blood Cancer. 2018 Sep;65(9):e27227. doi: 10.1002/pbc.27227. Epub 2018 Jun 19. Pediatr Blood Cancer. 2018. PMID: 29923370 Review.

3

Pediatric Cancer Immunotherapy: Opportunities and Challenges.

Wedekind MF, Denton NL, Chen CY, Cripe TP. Wedekind MF, et al. Paediatr Drugs. 2018 Oct;20(5):395-408. doi: 10.1007/s40272-018-0297-x. Paediatr Drugs. 2018. PMID: 29948928 Free PMC article. Review.

4

Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens.

Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP. Wedekind MF, et al. Pediatr Blood Cancer. 2018 Nov;65(11):e27313. doi: 10.1002/pbc.27313. Epub 2018 Jul 17. Pediatr Blood Cancer. 2018. PMID: 30015384

5

Oncolytic virus and PD-1/PD-L1 blockade combination therapy.

Chen CY, Hutzen B, Wedekind MF, Cripe TP. Chen CY, et al. Among authors: wedekind mf. Oncolytic Virother. 2018 Jul 31;7:65-77. doi: 10.2147/OV.S145532. eCollection 2018. Oncolytic Virother. 2018. PMID: 30105219 Free PMC article. Review.

6

Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma.

Wedekind MF, Cripe TP. Wedekind MF, et al. Adv Exp Med Biol. 2020;1258:77-89. doi: 10.1007/978-3-030-43085-6_5. Adv Exp Med Biol. 2020. PMID: 32767235 Review.

7

Childhood cancer data initiative: Status report.

Jagu S, Mardis ER, Wedekind MF, Widemann BC, Kingery RK, Gonzalez SL, Shern JF, Reaman GH. Jagu S, et al. Among authors: wedekind mf. Pediatr Blood Cancer. 2024 Feb;71(2):e30745. doi: 10.1002/pbc.30745. Epub 2023 Oct 27. Pediatr Blood Cancer. 2024. PMID: 37889049

8

Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature.

Wedekind MF, Saraf A, Willen F, Audino AN. Wedekind MF, et al. J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e278-e281. doi: 10.1097/MPH.0000000000002147. J Pediatr Hematol Oncol. 2022. PMID: 33769385 Review.

9

The Effects of Hospital Length of Stay on Readmissions for Children With Newly Diagnosed Acute Lymphoblastic Leukemia.

Wedekind MF, Dennis R, Sturm M, Koch T, Stanek J, O'Brien SH. Wedekind MF, et al. J Pediatr Hematol Oncol. 2016 Jul;38(5):329-33. doi: 10.1097/MPH.0000000000000559. J Pediatr Hematol Oncol. 2016. PMID: 26989914

10

Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.

Wedekind MF, Ranalli M, Shah N. Wedekind MF, et al. Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26586. Epub 2017 Apr 18. Pediatr Blood Cancer. 2017. PMID: 28417541

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters